CL2014001539A1 - Compuestos derivados de pirazolopiridina, inhibidores de los receptores de fgf; proceso para preparar; composición farmaceutica; combinacion farmaceutica; y su uso para tratar y prevenir el cancer, especialmente carcinomas vascularizados tal como de pulmon, mama, prostata, pancreatico, entre otros. - Google Patents
Compuestos derivados de pirazolopiridina, inhibidores de los receptores de fgf; proceso para preparar; composición farmaceutica; combinacion farmaceutica; y su uso para tratar y prevenir el cancer, especialmente carcinomas vascularizados tal como de pulmon, mama, prostata, pancreatico, entre otros.Info
- Publication number
- CL2014001539A1 CL2014001539A1 CL2014001539A CL2014001539A CL2014001539A1 CL 2014001539 A1 CL2014001539 A1 CL 2014001539A1 CL 2014001539 A CL2014001539 A CL 2014001539A CL 2014001539 A CL2014001539 A CL 2014001539A CL 2014001539 A1 CL2014001539 A1 CL 2014001539A1
- Authority
- CL
- Chile
- Prior art keywords
- pyrazolopyridine
- carcinomas
- pancreatic
- prostate
- breast
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1161589A FR2984325A1 (fr) | 2011-12-14 | 2011-12-14 | Derives de pyrazolopyridine, leur procede de preparation et leur application en therapeutique |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2014001539A1 true CL2014001539A1 (es) | 2014-10-17 |
Family
ID=47458918
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2014001539A CL2014001539A1 (es) | 2011-12-14 | 2014-06-11 | Compuestos derivados de pirazolopiridina, inhibidores de los receptores de fgf; proceso para preparar; composición farmaceutica; combinacion farmaceutica; y su uso para tratar y prevenir el cancer, especialmente carcinomas vascularizados tal como de pulmon, mama, prostata, pancreatico, entre otros. |
Country Status (23)
Country | Link |
---|---|
US (2) | US20140350006A1 (es) |
EP (1) | EP2791137B1 (es) |
JP (2) | JP6214551B2 (es) |
KR (1) | KR102012058B1 (es) |
CN (2) | CN104114555B (es) |
AU (1) | AU2012351712B2 (es) |
BR (1) | BR112014014452A2 (es) |
CA (1) | CA2857749A1 (es) |
CL (1) | CL2014001539A1 (es) |
CO (1) | CO7000778A2 (es) |
DK (1) | DK2791137T3 (es) |
EA (1) | EA027421B1 (es) |
ES (1) | ES2719444T3 (es) |
FR (1) | FR2984325A1 (es) |
HK (1) | HK1198442A1 (es) |
IL (1) | IL232906A (es) |
MA (1) | MA35841B1 (es) |
MX (1) | MX358422B (es) |
PH (1) | PH12014501258A1 (es) |
PL (1) | PL2791137T3 (es) |
PT (1) | PT2791137T (es) |
SG (2) | SG10201510204QA (es) |
WO (1) | WO2013087744A1 (es) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2984325A1 (fr) * | 2011-12-14 | 2013-06-21 | Sanofi Sa | Derives de pyrazolopyridine, leur procede de preparation et leur application en therapeutique |
US10138235B2 (en) | 2011-12-14 | 2018-11-27 | Sanofi | Pyrazolopyridine derivatives, preparation process therefor and therapeutic use thereof |
US20150344855A1 (en) | 2013-01-16 | 2015-12-03 | INSERM (Institut National de la Santé et de la Recherche Médicale | A Soluble Fibroblast Growth Factor Receptor 3 (FGR3) Polypeptide For Use In The Prevention Or Treatment Of Skeletal Growth Retardation Disorders |
AR094812A1 (es) | 2013-02-20 | 2015-08-26 | Eisai R&D Man Co Ltd | Derivado de piridina monocíclico como inhibidor del fgfr |
KR102244719B1 (ko) | 2013-03-15 | 2021-04-26 | 플렉시콘 인코퍼레이티드 | 헤테로시클릭 화합물 및 그의 용도 |
US20140303121A1 (en) | 2013-03-15 | 2014-10-09 | Plexxikon Inc. | Heterocyclic compounds and uses thereof |
PL3007694T3 (pl) * | 2013-06-14 | 2018-12-31 | Sanofi | Pochodne pirazolopirydynowe do zastosowania w leczeniu nowotworu pęcherza moczowego |
SG11201700703XA (en) | 2014-08-18 | 2017-03-30 | Eisai R&D Man Co Ltd | Salt of monocyclic pyridine derivative and crystal thereof |
WO2017053604A1 (en) * | 2015-09-23 | 2017-03-30 | The Regents Of The University Of California | Potent antiviral pyrazolopyridine compounds |
SG11201900074WA (en) | 2016-07-07 | 2019-02-27 | Therachon Sas | Soluble fibroblast growth factor receptor 3 (sfgfr3) polypeptides and uses thereof |
WO2019075243A1 (en) | 2017-10-13 | 2019-04-18 | Plexxikon Inc. | SOLID FORMS OF A COMPOUND FOR MODULATING KINASES |
EP3752150A1 (en) * | 2018-02-16 | 2020-12-23 | UCB Biopharma SRL | Pharmaceutical 6,5 heterobicyclic ring derivatives |
SG11202007591RA (en) | 2018-03-28 | 2020-09-29 | Eisai R&D Man Co Ltd | Therapeutic agent for hepatocellular carcinoma |
CN108774224B (zh) * | 2018-04-23 | 2020-10-30 | 浙江大学 | 吡唑并[3,4-b]吡啶类化合物及其制备方法和应用 |
CN110833556A (zh) * | 2018-08-15 | 2020-02-25 | 广西梧州制药(集团)股份有限公司 | 吡唑并嘧啶衍生物在治疗肝纤维化的用途 |
WO2020178316A1 (en) * | 2019-03-05 | 2020-09-10 | Aziende Chimiche Riunite Angelini Francesco - A.C.R.A.F. S.P.A. | 5- or 7-azaindazoles as beta-lactamase inhibitors |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006050076A1 (en) * | 2004-10-29 | 2006-05-11 | Janssen Pharmaceutica, N.V. | Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders |
DE102004061288A1 (de) * | 2004-12-14 | 2006-06-29 | Schering Ag | 3-Amino-Pyrazolo[3,4b]pyridine als Inhibitoren von Proteintyrosinkinasen, deren Herstellung und Verwendung als Arzneimittel |
US20080300267A1 (en) * | 2005-05-16 | 2008-12-04 | Barun Okram | Compounds and Compositions as Protein Kinase Inhibitors |
US7541367B2 (en) * | 2005-05-31 | 2009-06-02 | Janssen Pharmaceutica, N.V. | 3-benzoimidazolyl-pyrazolopyridines useful in treating kinase disorders |
FR2889526B1 (fr) * | 2005-08-04 | 2012-02-17 | Aventis Pharma Sa | 7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation |
CA2662031A1 (en) * | 2006-09-06 | 2008-03-13 | F. Hoffmann-La Roche Ag | Heteroaryl derivatives as protein kinase inhibitors |
KR20090031122A (ko) * | 2007-09-21 | 2009-03-25 | 주식회사 중외제약 | 인다졸 골격을 함유하는 화합물, 이의 제조방법 및 상기화합물을 함유하는 약제학적 조성물 |
ES2399945T3 (es) * | 2007-11-30 | 2013-04-04 | Pfizer Limited | Agonistas novedosos de los receptores de glucocorticoides |
US8263610B2 (en) * | 2008-12-30 | 2012-09-11 | Arqule, Inc. | Substituted imidazolyl-5,6-dihydrobenzo[N]isoquinoline compounds |
FR2951172B1 (fr) * | 2009-10-13 | 2014-09-26 | Pf Medicament | Derives pyrazolopyridines en tant qu'agent anticancereux |
PL3001903T3 (pl) * | 2009-12-21 | 2018-03-30 | Samumed, Llc | 1H-pirazolo[3,4-b]pirydyny i ich zastosowania terapeutyczne |
WO2012019954A1 (en) * | 2010-08-12 | 2012-02-16 | Evotec (Uk) Ltd. | Pyrazolopyridine compounds as pde10a inhibitors |
FR2984325A1 (fr) * | 2011-12-14 | 2013-06-21 | Sanofi Sa | Derives de pyrazolopyridine, leur procede de preparation et leur application en therapeutique |
-
2011
- 2011-12-14 FR FR1161589A patent/FR2984325A1/fr active Pending
-
2012
- 2012-12-13 CN CN201280069679.9A patent/CN104114555B/zh active Active
- 2012-12-13 BR BR112014014452A patent/BR112014014452A2/pt not_active Application Discontinuation
- 2012-12-13 PL PL12808328T patent/PL2791137T3/pl unknown
- 2012-12-13 ES ES12808328T patent/ES2719444T3/es active Active
- 2012-12-13 PT PT12808328T patent/PT2791137T/pt unknown
- 2012-12-13 AU AU2012351712A patent/AU2012351712B2/en not_active Ceased
- 2012-12-13 SG SG10201510204QA patent/SG10201510204QA/en unknown
- 2012-12-13 CN CN201610708994.1A patent/CN106317056B/zh active Active
- 2012-12-13 KR KR1020147019030A patent/KR102012058B1/ko active IP Right Grant
- 2012-12-13 JP JP2014546500A patent/JP6214551B2/ja active Active
- 2012-12-13 EA EA201491149A patent/EA027421B1/ru not_active IP Right Cessation
- 2012-12-13 SG SG11201402851TA patent/SG11201402851TA/en unknown
- 2012-12-13 MX MX2014007168A patent/MX358422B/es active IP Right Grant
- 2012-12-13 US US14/364,420 patent/US20140350006A1/en not_active Abandoned
- 2012-12-13 WO PCT/EP2012/075328 patent/WO2013087744A1/en active Application Filing
- 2012-12-13 DK DK12808328.4T patent/DK2791137T3/en active
- 2012-12-13 CA CA2857749A patent/CA2857749A1/en not_active Abandoned
- 2012-12-13 EP EP12808328.4A patent/EP2791137B1/en active Active
-
2014
- 2014-06-01 IL IL232906A patent/IL232906A/en active IP Right Grant
- 2014-06-04 PH PH12014501258A patent/PH12014501258A1/en unknown
- 2014-06-11 CL CL2014001539A patent/CL2014001539A1/es unknown
- 2014-07-02 MA MA37174A patent/MA35841B1/fr unknown
- 2014-07-10 CO CO14149160A patent/CO7000778A2/es unknown
- 2014-11-26 HK HK14111927A patent/HK1198442A1/xx unknown
-
2017
- 2017-03-07 US US15/451,970 patent/US20170231998A1/en not_active Abandoned
- 2017-07-07 JP JP2017133321A patent/JP2017206544A/ja not_active Withdrawn
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2014001539A1 (es) | Compuestos derivados de pirazolopiridina, inhibidores de los receptores de fgf; proceso para preparar; composición farmaceutica; combinacion farmaceutica; y su uso para tratar y prevenir el cancer, especialmente carcinomas vascularizados tal como de pulmon, mama, prostata, pancreatico, entre otros. | |
CR20150368A (es) | Inhibidores de histona desmetilasa | |
CL2015001790A1 (es) | Compuestos derivados de 3,4-dihidroisoquinolina sustituidos, inhibidores de prmt5; composicion farmaceutica; kit farmaceutico; metodo de inhibicion de prmt5; metodo para tratar la expresion de un gen; metodo para alterar la transcripcion; metodo de tratamiento de un trastorno tal como cancer, diabetes y obesisdad, entre otros. | |
PH12017502141A1 (en) | Compounds and their methods of use | |
CL2015001731A1 (es) | Compuestos inhibidores de autotaxina; composicion y combinacion farmaceutica; y uso en el tratamiento de enfermedades tales como fibrosis, prurito, cancer, entre otras. | |
CL2014002873A1 (es) | Compuestos derivados de pirimidin-amina o triazin-amina, inhibidores de adn-pk; composicion farmaceutica; y su uso para el tratamiento del cancer. | |
AR082340A1 (es) | Metodos y composiciones para la terapia del cancer de higado | |
AR091837A1 (es) | Compuestos para inmunoterapia dirigida | |
CL2016000227A1 (es) | Nueva inmunoterapia contra diversos tumores como el cáncer de pulmón, incluido el carcinoma de pulmón amicrocítico (nsclc) | |
CL2012002189A1 (es) | Compuestos derivados de pirrolidina-2-carboxamidas sustituidas; inhibidores de la interaccion mdm2-p53; composicion farmaceutica; y su uso para el tratamiento del cancer, en particular de tumores solidos. | |
DK2922828T3 (da) | 4,6-diamino-pyrimidin-derivater som bmi-1-inhibitorer til at behandle cancer | |
CL2014001065A1 (es) | Compuestos derivados de piridopirazinas; composicion farmaceutica que los comprende; y su uso para la prevencion o el tratamiento de un estado patologico o afeccion mediada por una fgfr cinasa tal como cancer. | |
ECSP13012978A (es) | Inhibidores de glucosilceramida sintasa | |
CL2008001047A1 (es) | Compuestos derivados de difenil-dihidro-imidazopiridinonas; inhibidores de mdm2-p53;composicion farmaceutica;y uso para preparar un medicamento destinado al tratamiento o control de tumores solidos,tales como:tumores de mama.de colon,de pulmon o de prostata. | |
CL2013001093A1 (es) | Compuestos triciclicos inhibidores de la quinasa pi3 (pi3k); composicion farmaceutica que los comprende; metodo para tratar el cancer; y su uso para el tratamiento del cancer . | |
CL2012003415A1 (es) | Compuestos derivados de 2-oxo-piperidina y 1,1-dioxido-tiazina, inhibidores de mdm2; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer . | |
CU24167B1 (es) | Derivados de triazolopirazinas sustituidas como inhibidores del receptor c-met o hgf para tratar el cáncer | |
EP2714081A4 (en) | METHODS, COMPOSITIONS AND KIT FOR CREAM TREATMENT | |
HK1195299A1 (zh) | 氮雜環丁烷化合物,組合物和它們作為可溶環氧化物水解酶的抑制劑的用途 | |
AU2016297823B2 (en) | Methods for better delivery of active agents to tumors | |
MX2014012477A (es) | Inhibidores pirrolopirazona de tanquirasa. | |
MX360774B (es) | Antagonistas de progesterona. | |
CL2014000998A1 (es) | Compuestos heterociclicos derivados de azepan-4-ona, inhibidores de la actividad desubiquitinante; composicion farmaceutica; uso para tratar cancer resistente a la quimioterapia. | |
CL2013002823A1 (es) | Compuestos derivados de morfolinotieno[3,2-d]pirimidin-6-il-metil-(metilamino)-n-hidroxipirimidina-5-carboxamida, inhibidores de la pi3 quinasa; composicion farmaceutica que los comprende; su uso en el tratamiento de un trastorno de proliferacion celular tal como el cancer. | |
CL2014002845A1 (es) | Compuestos derivados de pirazol inhibidores de sglt1; metodo para tratar la diabetes; composicion farmaceutica; uso del compuesto para el tratamiento de la diabetes tipo 1 y tipo 2. |